Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Inclusion Criteria: * Diagnosis of a relapse or refractory (r/r) B cell lymphoma, for which treatment with tisagenleucel (Kymriah), Axicabtagene (Yescarta) or Lisocabtagene Maraleucel (Breyanzi) is planned, including : * diffuse large B-cell lymphoma (DLBCL) not otherwise specified, * high grade B-cell lymphoma * DLBCL arising from follicular lymphoma * Primary mediastinal B cell lymphoma * Follicular lymphoma grade 3B * And considered at high risk for progression after CAR-T therapy by meeting one or more of the following factors: * refractory to last line of therapy/remission of less than 12 months * myc over expression \>40% in any prior biopsy or bcl2/bcl6 and c-myc re-arrangement (double/triple hit) * 2 sites of extranodal disease * IPI ≥ 3 * Elevated LDH at the time of relapse * Has secured coverage for Kymriah, Yescarta,Breyanzi administration * Age 18 years or older at the time of signing the consent * ECOG Performance status of 0, 1, or 2 * Adequate bone marrow reserve (may be transfusion dependent) * Adequate organ function at enrollment and within 14 days of planned E7777 treatment as defined in Section 4.1.7 * Hemodynamically stable and LVEF ≥ 50% confirmed by echocardiogram or MUGA * Grade 1 dyspnea (CTCAE v5) and SpO2 \> 91% on room air * Sexually active females of child-bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy * Provides voluntary written consent prior to the performance…